BAT-8001

重组人源化抗HER2单克隆抗体-美登素偶联物

Report date: 2024/02/05 13:55:52

Base Information

Drug NameBAT-8001

Drug Alias NameAnti-ErbB2 antibody drug conjugateAnti-HER2 antibody drug conjugateBAT-8001

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > MC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Maytansine derivative payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionTubulin polymerisation inhibitorsTubulin inhibitorsReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsTubulinReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSolid tumoursBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaDiscontinued

Originator CompaniesBio-Thera Solutions Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A

Inactive CompaniesBio-Thera Solutions Ltd

Active IndicationsN/A

Inactive IndicationsSolid tumoursBreast Neoplasms

Other Information

ATC CodeN/A